Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose TRG035 study in healthy adult men
jRCT2051240154Phase 1Completed
- Sponsor
- Toregem BioPharma
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anodontia comparing TRG035 with Placebo (2 arms). Primary endpoint: Safety. Started Oct 2024; status: completed.
02
Drugs
TRG035
03
Conditions
anodontia
Beyond the preview
Go deeper on jRCT2051240154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240154.